Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Chemotherapy-free Combination of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib in Combination With GA 101 in Patients With Previously Untreated Follicular Lymphoma and a High Tumor Burden

NCT02689869 is registered in ClinicalTrials.gov with Ludwig-Maximilians - University of Munich as lead sponsor.

NCT NCT02689869
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02689869 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Chemotherapy-free Combination of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib in Combination With GA 101 in Patients With Previously Untreated Follicular Lymphoma and a High Tumor Burden
Lead sponsor
Ludwig-Maximilians - University of Munich
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2016
Completion date
July 31, 2022
Enrollment
98 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

indolent non-hodgkin lymphoma